What is the Service? It's the process of using SELEX (Systematic Evolution of Ligands by EXponential Enrichment) to identify single-stranded DNA or RNA aptamers that can bind to a target cytokine. The service takes you from target selection to delivering validated aptamer candidates. Standard Workflow (What the Provider Does) Project Scoping & Target Preparation: Target: You specify the cytokine (e.g., TNF-α, IL-6, IFN-γ). The provider may require you to supply the purified, recombinant protein or offer to procure/produce it. Counter-SELEX: A critical step to ensure specificity. The provider will use related proteins (e.g., other cytokines, serum proteins) to eliminate aptamers that bind non-specifically. Library Design & SELEX Cycle: Starts with a vast random oligonucleotide library (10^14 - 10^15 unique sequences). Iterative rounds (8-15+) of: Binding: Incubating the library with the target cytokine. Partitioning: Separating bound from unbound sequences (e.g., via immobilization on beads, filters, or capillary electrophoresis). Amplification: PCR (for DNA) or RT-PCR (for RNA) to enrich the binding sequences. Stringency Increase: Gradually increasing washing rigor and introducing counter-selection to drive selection of high-affinity, specific binders. Next-Generation Sequencing (NGS) & Bioinformatics: After the final rounds, the enriched pool is sequenced using NGS. Bioinformatics tools analyze the data to identify enriched sequence families, consensus motifs, and predict secondary structures.…
What is an Aptamer? An aptamer is a short, single-stranded oligonucleotide (DNA or RNA) that folds into a unique 3D structure, allowing it to bind to a specific target molecule (like a protein) with similar specificity to an antibody. They are often called "chemical antibodies." Why Use a Screening Service Instead of In-House Development? Expertise & Equipment: The screening process (SELEX) requires specialized skills, robotics, and next-generation sequencing (NGS) infrastructure. Time & Cost Efficiency: Outsourcing can be faster and more cost-effective than setting up a new, complex pipeline. Higher Success Rate: Experienced providers have optimized protocols for difficult targets (e.g., membrane proteins, toxic proteins). The Core Process: SELEX The standard method is SELEX (Systematic Evolution of Ligands by EXponential Enrichment). A professional service will offer advanced variants of this process. A Typical Service Workflow: Project Consultation & Design: Target Characterization: Discussion about your protein (purified? membrane-bound? post-translational modifications?). Selection Strategy: Choosing the best SELEX method (e.g., Capillary Electrophoresis-SELEX (CE-SELEX) for very high affinity, Cell-SELEX for cell-surface targets, Toggle-SELEX for cross-species specificity). Counter-Selection: Designing the process to avoid binding to non-target proteins (e.g., carrier proteins, related isoforms). Library Synthesis & Preparation: Creation of a vast random oligonucleotide library (typically 10¹³ - 10¹⁵ unique sequences). The Selection Rounds (Cycles of SELEX): Binding: Incubating the library with the…
What is an Aptamer? Aptamers are single-stranded DNA or RNA oligonucleotides that fold into specific 3D shapes, enabling them to bind to target molecules (proteins, small molecules, cells, viruses) with high affinity and specificity, similar to antibodies. They are often called "chemical antibodies." Why Use Aptamer Screening Services in Drug Discovery? Efficiency: Outsourcing to experts with specialized platforms (SELEX) accelerates discovery. Cost-Effectiveness: Avoids capital investment in complex SELEX and NGS infrastructure. Expertise: Leverages specialized knowledge in oligonucleotide chemistry, bioinformatics, and target biology. Focus: Allows internal teams to concentrate on downstream therapeutic development. Core Components of an Aptamer Screening Service A full-service provider typically offers an end-to-end pipeline: 1. Project Design & Target Preparation Consultation: Defining the target (recombinant protein, cell surface marker, whole cell), desired affinity (nM-pM), and specificity (e.g., against homologs). Counter-SELEX Strategy: Planning to eliminate binders to non-desired epitopes or related targets to ensure high specificity. 2. In Vitro Selection (SELEX) The core technology is SELEX (Systematic Evolution of Ligands by EXponential enrichment). Advanced variants are used for complex targets: Protein-SELEX: For purified recombinant proteins. Cell-SELEX: For membrane proteins in their native conformation on live cells; identifies aptamers for diseased vs. healthy cells. Tissue-SELEX: For even more complex biological environments. Capture-SELEX: For small molecules that are difficult to immobilize. High-Throughput SELEX (HT-SELEX): Uses NGS early…
Core Technology: SELEX The foundation of all these services is the SELEX process, an in vitro method to select aptamers from a vast random library (typically 10^13 - 10^15 unique sequences). The library is incubated with the target, unbound sequences are washed away, and bound sequences are eluted and amplified by PCR (for DNA) or RT-PCR (for RNA). This cycle is repeated 8-15 times to enrich for the tightest binders. Services for Protein Targets This is the most common application, as aptamers are often touted as "chemical antibodies." 1. Standard Protein SELEX: Target: Purified, recombinant proteins (e.g., cytokines, receptors, enzymes, viral capsids). Key Considerations: Protein Purity & Conformation: Critical for success. Services often require >90% purity and verification of native folding. Immobilization: The protein is usually immobilized on beads (e.g., streptavidin/biotin, Ni-NTA/His-tag) to facilitate partitioning. Some services offer solution-phase SELEX to avoid conformation changes. Counter-Selection: To ensure specificity, libraries are pre-incubated with related proteins or the immobilization matrix to subtract non-specific binders. 2. Specialized SELEX for Complex Proteins: Membrane Protein SELEX: For receptors and channels. Requires special handling (e.g., use of nanodiscs, detergent micelles, or whole cells overexpressing the target). Post-Translationally Modified Protein SELEX: For targets where phosphorylation, glycosylation, etc., are essential for function. 3. Cell-SELEX (for Cell-Surface…
What is an Aptamer? An aptamer is a short, single-stranded DNA or RNA oligonucleotide that folds into a specific 3D structure, allowing it to bind to a target molecule (like a cytokine) with high affinity and specificity, akin to a monoclonal antibody. Why Target Cytokines with Aptamers? Cytokines are key signaling proteins in immune and inflammatory responses. Dysregulation is implicated in diseases like: Autoimmune disorders: Rheumatoid arthritis, psoriasis, inflammatory bowel disease. Cancer: Tumor microenvironment signaling. Cytokine Storms: Severe COVID-19, sepsis. Neurological diseases. Aptamers offer advantages over traditional antibody-based therapies: High Specificity: Can distinguish between closely related cytokine isoforms or conformational states. Controlled Synthesis: Chemically produced, no batch-to-batch variation. Modifiability: Easily conjugated with drugs, fluorophores, or nanoparticles. Low Immunogenicity: Less likely to cause an immune response. Stability: Generally more stable than proteins. The Aptamer Screening Service Workflow (SELEX) A professional service will manage the entire SELEX (Systematic Evolution of Ligands by EXponential Enrichment) process. Here’s a typical pipeline: Phase 1: Project Design & Target Preparation Consultation: Define the goal—neutralization, detection, or delivery. Target Selection: Which cytokine? (e.g., TNF-α, IL-6, IL-1β, IFN-γ). Requires a high-purity, bioactive protein. Services often help with recombinant expression/purification if needed. Library Design: A vast random-sequence oligonucleotide library (10^14-10^15 unique sequences) is the starting point. Libraries can be DNA, RNA, or contain modified…
Why Target Protein Kinases with Aptamers? Protein kinases are a large family of enzymes that regulate almost all cellular processes by phosphorylating target proteins. Their dysregulation is a hallmark of many diseases, especially cancer, making them prime therapeutic targets. Advantages of Aptamers over Traditional Kinase Inhibitors: High Specificity: Can be selected to distinguish between highly conserved kinase family members or even between active/inactive conformations. Modifiable Chemistry: Easy chemical modification for stability (e.g., 2'-F, 2'-O-methyl) and labeling (e.g., fluorophores, biotin). Non-Immunogenic: Unlike antibodies, they are chemically synthesized, reducing batch-to-batch variability. Reversible Inhibition: Typically act as competitive inhibitors, which can be desirable for certain therapeutic strategies. Cell-Permeable Versions: Spiegelmers (L-aptamers) or nanoparticle conjugation can enable intracellular targeting. Core Screening Service Workflow (SELEX) The service revolves around SELEX (Systematic Evolution of Ligands by EXponential Enrichment), specifically optimized for kinases. 1. Project Design & Library Selection: Target Definition: Which kinase? Which conformation (active, inactive, substrate-bound)? Which domain (catalytic, regulatory)? Library Design: Standard DNA/RNA libraries or modified (e.g., 2'-F pyrimidines for nuclease resistance). Library diversity is typically >10^14 unique sequences. 2. Target Preparation: Protein Quality is Critical: The kinase must be highly pure, correctly folded, and functional. Services often use recombinant kinases with tags (GST, His) for immobilization. Immobilization Strategy: Crucial step. Common methods include: Biotin-Streptavidin: Biotinylated…
Traditional SELEX (Systematic Evolution of Ligands by EXponential enrichment) is a method to select high-affinity, specific nucleic acid aptamers from a vast random library (10¹³-10¹⁵ sequences). The bottleneck has always been the final cloning and Sanger sequencing of only a few dozen candidates, which often misses rare, high-performance aptamers. NGS-assisted SELEX integrates Next-Generation Sequencing at multiple rounds of the SELEX process. This provides a massive, data-rich view of the entire evolutionary landscape, enabling intelligent selection and identification of the best aptamers. Typical Workflow of an NGS-Assisted SELEX Service A professional service provider will manage this entire pipeline: Project Design & Library Synthesis: Collaboration to define target (protein, small molecule, cell), counter-selection requirements, and library design (random region length, fixed primers for NGS). Parallel SELEX Execution: Performing the iterative selection process (binding, partitioning, amplification) across multiple rounds (usually 8-12). Key NGS Integration Points: Initial Library Analysis: Sequencing the naive library to confirm diversity and complexity. Monitoring Rounds (e.g., Rounds 3, 6, 9): Taking small samples from intermediate rounds for NGS. This is the critical advantage. It tracks: Sequence Enrichment: Which families are becoming more abundant. Diversity Collapse: When to stop selection before losing good candidates. Informed Decision-Making: Data guides adjustments in selection stringency for subsequent rounds. Final Round Deep Sequencing: Comprehensive NGS of…
